Comparable stake leader
OrbiMed Capital GP VIII LLC
SEC ownership of Kinnate Biopharma Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001797768.
Disclosed value leader
OrbiMed Capital GP VIII LLC
Comparable rows
0/2
Latest evidence
01 Mar 2024
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
OrbiMed Capital GP VIII LLC
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
01 Mar 2024
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001797768
- Issuer location
- San Diego, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Kinnate Biopharma Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
OrbiMed Capital GP VIII LLC
Disclosed value leader
OrbiMed Capital GP VIII LLC
Comparable rows
0/2
Latest evidence
01 Mar 2024
3/4/5
Highest disclosed value: $1,237,500
2 rows are not safely comparable across share classes.
Quick read
OrbiMed Capital GP VIII LLC has the largest disclosed position value at $1.24M.
0 of 2 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens OrbiMed Capital GP VIII LLC's linked filing trail.
Disclosed position value
Top 2
OrbiMed Capital GP VIII LLC
$1.24M
Richard Thomas Williams
$175.1K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-2 of 2 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| OrbiMed Capital GP VIII LLC |
3/4/5
Director, 10%+ Owner
|
—
class O/S missing
|
$1,237,500
550,000 shares
|
— | 17 Feb 2023 |
| Richard Thomas Williams |
3/4/5
CHIEF MEDICAL OFFICER
|
—
class O/S missing
|
$175,053
67,588 shares
|
— | 01 Mar 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 28 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-16 of 16 reporting-owner rows connected to Kinnate Biopharma Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
16
Largest Forms 3/4/5 holder
OrbiMed Capital GP VIII LLC
Net 12M change
$0
Latest report
03 Apr 2024
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| OrbiMed Capital GP VIII LLC | Director, 10%+ Owner | $1,237,500 | Mixed | 17 Feb 2023 | ||
| Richard Thomas Williams | Chief Medical Officer | $175,053 | Mixed | 01 Mar 2024 | ||
| ORBIMED ADVISORS LLC | Director, 10%+ Owner | $0 | Mixed | 03 Apr 2024 | ||
| Carl L. Gordon | Director, 10%+ Owner | $0 | Mixed | 03 Apr 2024 | ||
| James B. Tananbaum | Director, 10%+ Owner | $0 | Mixed | 03 Apr 2024 | ||
| Neha Krishnamohan | Chief Financial Officer | $0 | Mixed | 03 Apr 2024 | ||
| Flaherty Keith T. | Director | $0 | Mixed | 03 Apr 2024 | ||
| Foresite Capital Management IV, LLC | 10%+ Owner | $0 | Mixed | 03 Apr 2024 | ||
| Nima Farzan | CHIEF EXECUTIVE OFFICER, Director | $0 | Mixed | 03 Apr 2024 | ||
| Mark A. Meltz | Coo General Counsel Secretary | $0 | Mixed | 03 Apr 2024 | ||
| Jill DeSimone | Director | Mixed | 03 Apr 2024 | |||
| Michael E. Rome | Director | Mixed | 03 Apr 2024 | |||
| Helen Sabzevari | Director | Mixed | 03 Apr 2024 | |||
| Dean J. Mitchell | Director | Mixed | 03 Apr 2024 | |||
| Alsup Laurie Smaldone | Director | Mixed | 03 Apr 2024 | |||
| Melissa B. Epperly | Director | Mixed | 03 Apr 2024 |
Recent insider transactions for Kinnate Biopharma Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.